Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists
Mary Beth Nierengarten is a writer, editor and journalist with over 25 years of medical communications experience. She is a regular contributor to a number of online and print publications and writes in most clinical areas, as well as on health policy and economic issues. She lives in Minneapolis and can be reached at [email protected].
Articles by Mary Beth Nierengarten
ACR/ARHP Annual Meeting 2012: Early Signs of Rheumatoid Arthritis May Appear Outside the Joints
Evidence that suggests rheumatoid arthritis (RA) starts in mucosal sites such as the oral cavity and lung may lead to improved treatment and prevention of the disease
ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront
Studies addressing rheumatoid arthritis (RA) flares, a potential new drug for psoriatic arthritis, and a novel agent in the treatment of active RA are among the highlights
ACR/ARHP Annual Meeting 2012: Identify Compliance Risks to Avoid Violating Medicare Rules
Rheumatologists should develop a plan to keep in step with federal regulations
ACR/ARHP Annual Meeting 2012: How to Manage Gout Effectively in the Context of Comorbid Conditions
Comorbid conditions such as chronic kidney disease and cardiovascular disease can complicate gout management, but effective treatment and preventive strategies are available
- « Previous Page
- 1
- …
- 14
- 15
- 16